InMode's fundamentals remain strong despite guidance cuts, macro headwinds, and governance disputes, making current negative sentiment appear overdone. Valuation is compelling at just 9.3x forward EPS and ~6% FCF yield, with a robust cash buffer and capital-light business model offering downside protection. Share buybacks are accelerating, shrinking share count and compounding per-share value, even if revenues remain flat, providing a powerful catalyst for upside.
InMode's Q1 2025 earnings reveal a 3% YoY revenue decline and margin compression, signaling continued macroeconomic pressures and underutilization of installed platforms. Management's revised 2025 guidance lowers profitability expectations, reflecting ongoing challenges in the U.S. market and less profitable international expansion. Despite a strong balance sheet, past strategic missteps and ineffective cash allocation raise concerns about future shareholder value and growth prospects.
InMode Ltd. (NASDAQ:INMD ) Q1 2025 Earnings Conference Call April 28, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - CEO Yair Malca - CFO Conference Call Participants Matt Miksic - Barclays Danielle Antalffy - UBS Matt Taylor - Jefferies Caitlin Cronin - Canaccord Genuity Mike Matson - Needham & Company Sam Eiber - BTIG Dane Reinhardt - Baird Operator Good day, and welcome to InMode's First Quarter 2025 Earnings Results Conference Call.
InMode (INMD) came out with quarterly earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.45 per share a year ago.
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InMode (INMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
I upgrade InMode to Buy due to improved capital allocation, including significant share buybacks and potential for record dividends. Despite a 20% revenue decline in 2024, InMode remains a strong cash generator, with $600 million in cash. Conservative DCF valuation suggests a fair value of $21.67 per share, implying a 22.5% potential upside from current levels.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
InMode is significantly undervalued, with strong cash flow, international expansion, and investments in research and marketing driving future revenue and free cash flow growth. The company benefits from the booming non-invasive plastic surgery market, expected to grow at a 14% CAGR from 2023 to 2030. INMD's stock repurchase program and substantial investments in bonds and bank deposits are expected to boost stock price and financial stability.
InMode Ltd. (NASDAQ:INMD ) Q4 2024 Results Conference Call February 4, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Rafael Lickerman - Vice President, Finance Conference Call Participants Danielle Antalffy - UBS Matt Miksic - Barclays Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Matson - Needham & Company Jeff Johnson - Baird Sam Eiber - BTIG Operator Good day, and welcome to the InMode Fourth Quarter and Full Year 2024 Earnings Results Conference Call.
InMode Ltd. boasts superior fundamentals, yet trades at undervalued market multiples due to its unique risk profile. The company is a leader in the global aesthetics market with proprietary RF-based technologies. InMode's robust balance sheet and high profit margins support a substantial margin of safety at current prices, despite risks.
I'm downgrading InMode from a 'Strong Buy' to a 'Buy' due to consistent guidance cuts and short-term demand issues. Despite recent performance issues and high interest rates, INMD still holds a strong cash position, has high margins, and offers a good long-term entry point with a solid earnings yield. The company's revenue forecasts for 2024 and 2025 have been lowered notably, indicating potential market saturation and weak demand.